{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T18:31:16Z","timestamp":1781721076277,"version":"3.54.5"},"reference-count":79,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"vor","delay-in-days":384,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["K22 CA258805"],"award-info":[{"award-number":["K22 CA258805"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["F 99 CA253754"],"award-info":[{"award-number":["F 99 CA253754"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006298","name":"S\u00e4chsische Aufbaubank","doi-asserted-by":"publisher","award":["EcoR1"],"award-info":[{"award-number":["EcoR1"]}],"id":[{"id":"10.13039\/501100006298","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007886","name":"Dana-Farber Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Chemical Biology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.chembiol.2022.08.003","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T10:35:43Z","timestamp":1662460543000},"page":"1470-1481.e31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["Exploring the target scope of KEAP1 E3 ligase-based PROTACs"],"prefix":"10.1016","volume":"29","author":[{"given":"Guangyan","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel J.","family":"Henning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozhat","family":"Safaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Koide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rados\u0142aw P.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hojong","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inchul","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Eleuteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengnian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert T.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnam","family":"Nabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinghu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathanael S.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chembiol.2022.08.003_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ab.2008.10.044","article-title":"A set of baculovirus transfer vectors for screening of affinity tags and parallel expression strategies","volume":"385","author":"Abdulrahman","year":"2009","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.chembiol.2022.08.003_bib2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.apsb.2015.05.008","article-title":"Discovery of direct inhibitors of Keap1\u2013Nrf2 protein\u2013protein interaction as potential therapeutic and preventive agents","volume":"5","author":"Abed","year":"2015","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.chembiol.2022.08.003_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.37349\/etat.2020.00009","article-title":"Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors","volume":"1","author":"Arthur","year":"2020","journal-title":"Exploration of targeted anti-tumor therapy"},{"key":"10.1016\/j.chembiol.2022.08.003_bib4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00204-011-0674-5","article-title":"The cytoprotective role of the Keap1\u2013Nrf2 pathway","volume":"85","author":"Baird","year":"2011","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.chembiol.2022.08.003_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1146\/annurev-pharmtox-010715-103507","article-title":"Targeted protein degradation by small molecules","volume":"57","author":"Bondeson","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.chembiol.2022.08.003_bib6","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","article-title":"Targeting the C481S ibrutinib-resistance mutation in Bruton\u2019s tyrosine kinase using PROTAC-mediated degradation","volume":"57","author":"Buhimschi","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.chembiol.2022.08.003_bib7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","article-title":"The advantages of targeted protein degradation over inhibition: an RTK case study","volume":"25","author":"Burslem","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.chembiol.2022.08.003_bib8","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1021\/acs.jmedchem.9b01566","article-title":"Discovery of potent and selective epidermal growth factor receptor (EGFR) bifunctional small-molecule degraders","volume":"63","author":"Cheng","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.chembiol.2022.08.003_bib9","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1021\/acs.jmedchem.6b00228","article-title":"Monoacidic inhibitors of the Kelch-like ECH-associated protein 1: nuclear factor erythroid 2-related factor 2 (KEAP1: NRF2) protein\u2013protein interaction with high cell potency identified by fragment-based discovery","volume":"59","author":"Davies","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.chembiol.2022.08.003_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-11429-w","article-title":"Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations","volume":"10","author":"de Wispelaere","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2022.08.003_bib11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41586-020-2168-1","article-title":"Multispecific drugs herald a new era of biopharmaceutical innovation","volume":"580","author":"Deshaies","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2022.08.003_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nchembio.481","article-title":"Specific Btk inhibition suppresses B cell\u2013and myeloid cell\u2013mediated arthritis","volume":"7","author":"Di Paolo","year":"2011","journal-title":"Nat. Chem. Bio."},{"key":"10.1016\/j.chembiol.2022.08.003_bib13","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood-2018-07-862953","article-title":"Bruton tyrosine kinase degradation as a therapeutic strategy for cancer","volume":"133","author":"Dobrovolsky","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.chembiol.2022.08.003_bib14","doi-asserted-by":"crossref","first-page":"e38430","DOI":"10.7554\/eLife.38430","article-title":"Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome","volume":"7","author":"Donovan","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.chembiol.2022.08.003_bib15","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.cell.2020.10.038","article-title":"Mapping the degradable kinome provides a resource for expedited degrader development","volume":"183","author":"Donovan","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2022.08.003_bib16","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1021\/ja311795d","article-title":"A comprehensive mathematical model for three-body binding equilibria","volume":"135","author":"Douglass","year":"2013","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.chembiol.2022.08.003_bib17","series-title":"Abstract P5-04-18: ARV-471, an Oral Estrogen Receptor PROTAC Degrader for Breast Cancer (AACR)","author":"Flanagan","year":"2019"},{"key":"10.1016\/j.chembiol.2022.08.003_bib18","doi-asserted-by":"crossref","first-page":"11734","DOI":"10.1021\/jacs.9b13907","article-title":"Efficient targeted degradation via reversible and irreversible covalent PROTACs","volume":"142","author":"Gabizon","year":"2020","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.chembiol.2022.08.003_bib19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/acsmedchemlett.9b00597","article-title":"PROTAC technology: opportunities and challenges","volume":"11","author":"Gao","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.chembiol.2022.08.003_bib20","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.bmc.2019.02.048","article-title":"Cereblon versus VHL: hijacking E3 ligases against each other using PROTACs","volume":"27","author":"Girardini","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.chembiol.2022.08.003_bib21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.tibs.2014.02.002","article-title":"The Nrf2 regulatory network provides an interface between redox and intermediary metabolism","volume":"39","author":"Hayes","year":"2014","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.chembiol.2022.08.003_bib22","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1021\/jacs.1c03980","article-title":"Discovery of a covalent FEM1B recruiter for targeted protein degradation applications","volume":"144","author":"Henning","year":"2022","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.chembiol.2022.08.003_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.chembiol.2017.10.005","article-title":"A chemoproteomic approach to query the degradable kinome using a multi-kinase degrader","volume":"25","author":"Huang","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.chembiol.2022.08.003_bib24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.cbpa.2010.12.009","article-title":"Small molecule modulators of antioxidant response pathway","volume":"15","author":"Hur","year":"2011","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.chembiol.2022.08.003_bib25","doi-asserted-by":"crossref","first-page":"16023","DOI":"10.1074\/jbc.275.21.16023","article-title":"Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages","volume":"275","author":"Ishii","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.chembiol.2022.08.003_bib26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/bbrc.1997.6943","article-title":"An Nrf2\/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements","volume":"236","author":"Itoh","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.chembiol.2022.08.003_bib27","doi-asserted-by":"crossref","first-page":"126877","DOI":"10.1016\/j.bmcl.2019.126877","article-title":"Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties","volume":"30","author":"Jaime-Figueroa","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.chembiol.2022.08.003_bib28","doi-asserted-by":"crossref","first-page":"14481","DOI":"10.1002\/anie.202003500","article-title":"Mutant-selective allosteric EGFR degraders are effective against a broad range of drug-resistant mutations","volume":"59","author":"Jang","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.chembiol.2022.08.003_bib29","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1002\/anie.201901336","article-title":"Development of dual and selective degraders of cyclin-dependent kinases 4 and 6","volume":"58","author":"Jiang","year":"2019","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.chembiol.2022.08.003_bib30","doi-asserted-by":"crossref","first-page":"10837","DOI":"10.1021\/acs.jmedchem.6b00586","article-title":"Discovery and development of Kelch-like ECH-associated protein 1. nuclear factor erythroid 2-related factor 2 (KEAP1: NRF2) protein\u2013protein interaction inhibitors: achievements, challenges, and future directions","volume":"59","author":"Jiang","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.chembiol.2022.08.003_bib31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.chembiol.2017.10.011","article-title":"Small-molecule kinase downregulators","volume":"25","author":"Jones","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.chembiol.2022.08.003_bib32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.46.120604.141046","article-title":"Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway","volume":"47","author":"Kensler","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.chembiol.2022.08.003_bib33","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-X L PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.chembiol.2022.08.003_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-56177-5","article-title":"Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera","volume":"9","author":"Kim","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.chembiol.2022.08.003_bib35","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.tips.2020.02.006","article-title":"Critical assessment of targeted protein degradation as a research tool and pharmacological modality","volume":"41","author":"Kostic","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.chembiol.2022.08.003_bib36","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/anie.201507634","article-title":"Modular PROTAC design for the degradation of oncogenic BCR-ABL","volume":"55","author":"Lai","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.chembiol.2022.08.003_bib37","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/s00044-020-02526-3","article-title":"Targeted selective degradation of Bruton\u2019s tyrosine kinase by PROTACs","volume":"29","author":"Liu","year":"2020","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.chembiol.2022.08.003_bib38","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1038\/sj.emboj.7601243","article-title":"Structure of the Keap1: Nrf2 interface provides mechanistic insight into Nrf2 signaling","volume":"25","author":"Lo","year":"2006","journal-title":"EMBO J."},{"key":"10.1016\/j.chembiol.2022.08.003_bib39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejmech.2018.01.063","article-title":"Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway","volume":"146","author":"Lu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.chembiol.2022.08.003_bib40","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.chembiol.2021.01.005","article-title":"Chemoproteomics-enabled discovery of covalent RNF114-based degraders that mimic natural product function","volume":"28","author":"Luo","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.chembiol.2022.08.003_bib41","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/med.21257","article-title":"Small molecule modulators of K eap1-N rf2-ARE pathway as potential preventive and therapeutic agents","volume":"32","author":"Magesh","year":"2012","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.chembiol.2022.08.003_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-00954-1","article-title":"Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation","volume":"8","author":"Maniaci","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2022.08.003_bib43","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41589-018-0129-x","article-title":"SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate","volume":"14","author":"Matyskiela","year":"2018","journal-title":"Nat. Chem. Bio."},{"key":"10.1016\/j.chembiol.2022.08.003_bib79","doi-asserted-by":"crossref","first-page":"7150","DOI":"10.1021\/ac502040v","article-title":"MultiNotch MS3 enables accurate, sensitive, and multiplexed detection of differential expression across cancer cell line proteomes","volume":"86","author":"McAlister","year":"2014","journal-title":"Anal Chem."},{"key":"10.1016\/j.chembiol.2022.08.003_bib44","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","article-title":"PROTACs: an emerging therapeutic modality in precision medicine","volume":"27","author":"Nalawansha","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.chembiol.2022.08.003_bib45","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.2019.37.7_suppl.259","article-title":"ARV-110: an oral androgen receptor PROTAC degrader for prostate cancer","volume":"37","author":"Neklesa","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.chembiol.2022.08.003_bib46","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41589-018-0055-y","article-title":"Plasticity in binding confers selectivity in ligand-induced protein degradation","volume":"14","author":"Nowak","year":"2018","journal-title":"Nat. Chem. Bio."},{"key":"10.1016\/j.chembiol.2022.08.003_bib47","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1042\/BST20150069","article-title":"The Keap1\/Nrf2 pathway in health and disease: from the bench to the clinic","volume":"43","author":"O\u2019Connell","year":"2015","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.chembiol.2022.08.003_bib48","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-19-0959","article-title":"Selective alanine transporter utilization creates a targetable metabolic niche in pancreatic cancer","volume":"10","author":"Parker","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.chembiol.2022.08.003_bib49","series-title":"First-in-human Phase I Study of ARV-110, an Androgen Receptor (AR) PROTAC Degrader in Patients (Pts) with Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Following Enzalutamide (ENZ) And\/or Abiraterone (ABI)","author":"Petrylak","year":"2020"},{"key":"10.1016\/j.chembiol.2022.08.003_bib50","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1039\/D0MD00382D","article-title":"Selective degradation-inducing probes for studying cereblon (CRBN) biology","volume":"12","author":"Powell","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.chembiol.2022.08.003_bib51","doi-asserted-by":"crossref","first-page":"5738","DOI":"10.1002\/anie.201611281","article-title":"Degradation of the BAF complex factor BRD9 by heterobifunctional ligands","volume":"56","author":"Remillard","year":"2017","journal-title":"Angew. Chem., Int. Ed. Engl."},{"key":"10.1016\/j.chembiol.2022.08.003_bib52","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1\u2013Cullin\u2013F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2022.08.003_bib53","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1126\/science.aam7340","article-title":"Waste disposal\u2014an attractive strategy for cancer therapy","volume":"355","author":"Salami","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2022.08.003_bib54","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.chembiol.2021.04.011","article-title":"Targeted protein degradation: a promise for undruggable proteins","volume":"28","author":"Samarasinghe","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.chembiol.2022.08.003_bib55","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41589-020-00686-2","article-title":"Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes","volume":"17","author":"Schiemer","year":"2021","journal-title":"Nat. Chem. Bio."},{"key":"10.1016\/j.chembiol.2022.08.003_bib56","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3389\/fonc.2021.646971","article-title":"Proteolysis targeting chimeras for BTK efficiently inhibit B-cell receptor signaling and can overcome ibrutinib resistance in CLL cells","volume":"11","author":"Shorer Arbel","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.chembiol.2022.08.003_bib57","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41589-019-0304-8","article-title":"Harnessing the anti-cancer natural product nimbolide for targeted protein degradation","volume":"15","author":"Spradlin","year":"2019","journal-title":"Nat. Chem. Bio."},{"key":"10.1016\/j.chembiol.2022.08.003_bib58","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1039\/C8CC09541H","article-title":"PROTAC-mediated crosstalk between E3 ligases","volume":"55","author":"Steinebach","year":"2019","journal-title":"Chem. Commun."},{"key":"10.1016\/j.chembiol.2022.08.003_bib59","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1021\/acschembio.8b00693","article-title":"Homo-PROTACs for the chemical knockdown of cereblon","volume":"13","author":"Steinebach","year":"2018","journal-title":"ACS Chem. Bio."},{"key":"10.1016\/j.chembiol.2022.08.003_bib60","doi-asserted-by":"crossref","first-page":"7575","DOI":"10.1021\/acs.jmedchem.9b00871","article-title":"Potent and preferential degradation of CDK6 via proteolysis targeting chimera degraders","volume":"62","author":"Su","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.chembiol.2022.08.003_bib61","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41375-019-0440-x","article-title":"Degradation of Bruton\u2019s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas","volume":"33","author":"Sun","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.chembiol.2022.08.003_bib62","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41422-018-0055-1","article-title":"PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies","volume":"28","author":"Sun","year":"2018","journal-title":"Cell Res."},{"key":"10.1016\/j.chembiol.2022.08.003_bib63","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.freeradbiomed.2012.06.023","article-title":"Validation of the multiple sensor mechanism of the Keap1-Nrf2 system","volume":"53","author":"Takaya","year":"2012","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.chembiol.2022.08.003_bib64","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1021\/acschembio.8b01094","article-title":"PROTAC-mediated degradation of Bruton\u2019s tyrosine kinase is inhibited by covalent binding","volume":"14","author":"Tinworth","year":"2019","journal-title":"ACS Chem. Bio."},{"key":"10.1016\/j.chembiol.2022.08.003_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-72491-9","article-title":"Bardoxolone conjugation enables targeted protein degradation of BRD4","volume":"10","author":"Tong","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.chembiol.2022.08.003_bib66","doi-asserted-by":"crossref","first-page":"273","DOI":"10.37349\/etat.2020.00018","article-title":"Current strategies for the design of PROTAC linkers: a critical review","volume":"1","author":"Troup","year":"2020","journal-title":"Exploration of Targeted Anti-Tumor Therapy"},{"key":"10.1016\/j.chembiol.2022.08.003_bib67","doi-asserted-by":"crossref","first-page":"15073","DOI":"10.1021\/jacs.1c04841","article-title":"Harnessing the E3 ligase KEAP1 for targeted protein degradation","volume":"143","author":"Wei","year":"2021","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.chembiol.2022.08.003_bib68","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Phthalimide conjugation as a strategy for in\u00a0vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2022.08.003_bib69","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-cancerbio-030518-055627","article-title":"The pleiotropic role of the KEAP1\/NRF2 pathway in cancer","volume":"4","author":"Wu","year":"2020","journal-title":"Annu. Rev. Cancer Biol."},{"key":"10.1016\/j.chembiol.2022.08.003_bib70","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1039\/C9CC08238G","article-title":"Protein degradation through covalent inhibitor-based PROTACs","volume":"56","author":"Xue","year":"2020","journal-title":"Chem. Commun."},{"key":"10.1016\/j.chembiol.2022.08.003_bib71","doi-asserted-by":"crossref","first-page":"18370","DOI":"10.1021\/jacs.9b06422","article-title":"Light-induced protein degradation with photocaged PROTACs","volume":"141","author":"Xue","year":"2019","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.chembiol.2022.08.003_bib72","first-page":"1","article-title":"Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth","volume":"5","author":"Yao","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.chembiol.2022.08.003_bib73","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.apsb.2020.05.001","article-title":"Selective inhibition of CDK4\/6: a safe and effective strategy for developing anticancer drugs","volume":"11","author":"Yuan","year":"2021","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.chembiol.2022.08.003_bib74","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.chembiol.2019.12.006","article-title":"Exploring targeted degradation strategy for oncogenic KRASG12C","volume":"27","author":"Zeng","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.chembiol.2022.08.003_bib75","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41589-019-0279-5","article-title":"Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16","volume":"15","author":"Zhang","year":"2019","journal-title":"Nat. Chem. Bio."},{"key":"10.1016\/j.chembiol.2022.08.003_bib76","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1021\/jacs.1c00990","article-title":"DCAF11 supports targeted protein degradation by electrophilic proteolysis-targeting chimeras","volume":"143","author":"Zhang","year":"2021","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.chembiol.2022.08.003_bib77","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1021\/acs.jmedchem.8b01413","article-title":"Iterative design and optimization of initially inactive proteolysis targeting chimeras (PROTACs) identify VZ185 as a potent, fast, and selective von Hippel\u2013Lindau (VHL) based dual degrader probe of BRD9 and BRD7","volume":"62","author":"Zoppi","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.chembiol.2022.08.003_bib78","doi-asserted-by":"crossref","first-page":"E7285","DOI":"10.1073\/pnas.1803662115","article-title":"Delineating the role of cooperativity in the design of potent PROTACs for BTK","volume":"115","author":"Zorba","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Cell Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451945622003117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451945622003117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:51:06Z","timestamp":1778889066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451945622003117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":79,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2451945622003117"],"URL":"https:\/\/doi.org\/10.1016\/j.chembiol.2022.08.003","relation":{},"ISSN":["2451-9456"],"issn-type":[{"value":"2451-9456","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the target scope of KEAP1 E3 ligase-based PROTACs","name":"articletitle","label":"Article Title"},{"value":"Cell Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chembiol.2022.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}